Collegium Pharmaceutical, Inc. COLL Symproic and other — Product revenues, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net?
- Collegium Pharmaceutical, Inc. (COLL) reported symproic and other — product revenues, net of $3.61M in Q4 2025.
- How has Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net changed year-over-year?
- Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net decreased by 4.3% year-over-year, from $3.78M to $3.61M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net?
- Over 2 years (2023 to 2025), Collegium Pharmaceutical, Inc.'s symproic and other — product revenues, net has grown at a -6.4% compound annual growth rate (CAGR), from $16.5M to $14.45M.
- What does symproic and other — product revenues, net mean?
- Represents the net sales generated from the Symproic product line and associated secondary offerings after accounting for returns, discounts, and rebates. This metric is a key indicator of market demand and commercial performance for this specific segment of the company's pharmaceutical portfolio.